ƀ-Lactam/ƀ-Lactamase Inhibitor Combinations against Isolates from United States Medical Centers (2020ï2021)

INTRODUCTION

Pseudomonas aeruginosa

P. aeruginosa

the use of newer β-lactam/β-lactamase inhibitor (BL/BLI) combinations, such as ceftazidime-avibactam, ceftolozane-

in vitro

P. aeruginosa

METHODS

P. aeruginosa

consecutive isolates (1/patient) per infection type per year.